Skip to main content
SpringerLink
Log in

Chronic lymphocytic leukemia: ASH update 2014

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Abstract

At the annual meeting of the American Society of Hematology 2014 in San Francisco, a variety of important clinical trials covering topics like first-line immunochemotherapy, maintenance therapy with monoclonal antibodies as well as confirmatory data of novel therapies such as B-cell receptor or BCL2 inhibitors were presented. In view of these data new clinical standards have been set up and validated, respectively. Taken together, the data presented underscores the importance of immunochemotherapy despite the upcoming era of tyrosine kinase inhibitor treatment in chronic lymphocytic leukemia (CLL) as a standard for (ultra-) high-risk patients. Moreover, the concept of response consolidation/maintenance with the use of monoclonal anti-CD20 antibodies as applied for indolent lymphoma may also be clinically relevant for CLL.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Eichhorst B, Fink AM, Busch R, et al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 Study). Blood (ASH Annual Meeting Abstracts). 2014;124:19.

  2. Eichhorst B, Fink AM, Busch R, et al. Chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) versus bendamustine and rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a planned interim analysis of the CLL10 trial, an international, randomized study of the German CLL Study Group (GCLLSG). Blood (ASH Annual Meeting Abstracts). 2013;122:526.

    Google Scholar 

  3. Vidal L, Gafter-Gvili A, Salles G, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review an meta-analysis of randomized trials. J Natl Cancer Inst. 2011(23):1799–806.

  4. Greil R, Obrtlikova P, Smolej L, et al. Rituximab maintenance after chemoimmunotherapy induction in 1st and 2nd line improves progression free survival: planned interim analysis of the international randomized AGMT-CLL8/a Mabtenance Trial. Blood (ASH Annual Meeting Abstracts). 2014;124:20.

    Google Scholar 

  5. Van Oers MHJ, Kuliczkowski K, Smolej L, et al. Ofatumumab (OFA) maintenance prolongs PFS in relapsed CLL: prolong study interim analysis results. Blood (ASH Annual Meeting Abstracts). 2014;124:21.

    Article  Google Scholar 

  6. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010;463:88–92.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. O’Brien S, Jones JA, Couture S, et al. Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia with 17p deletion: results from the phase II RESONATE™-17 trial. Blood (ASH Annual Meeting Abstracts). 2014;124:327.

    Google Scholar 

  8. Furman R, Sharman JP, Coutre SE, et al. Idelalisib and Rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014, 370(11):997–1007.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Sharman JP, Coutre SE, Furman R, et al. Second interim analysis of a phase 3 study of idelalisib (ZYDELIG®) plus rituximab (R) for relapsed chronic lymphocytic leukemia (CLL): efficacy analysis in patient subpopulations with del(17p) and other adverse prognostic factors. Blood (ASH Annual Meeting Abstracts). 2014;124:330.

    Google Scholar 

  10. Roberts AW, Ma S, Brander DM, et al. Determination of recommended phase 2 dose of ABT-199 (GDC-0199) combined with rituximab (R) in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Blood (ASH Annual Meeting Abstracts). 2014;124:325.

    Google Scholar 

  11. Finn I, Oki Y, Patel M, et al. A phase 1 evaluation of duvelisib (IPI-145), a PI3K-d,g inhibitor, in patients with relapsed/refractory iNHL. Blood (ASH Annual Meeting Abstracts). 2014;124:802.

    Google Scholar 

  12. Jones JA, Geyer S, Andritsos LA, et al. Dinaciclib (SCH 727965) and ofatumumab for the treatment of relapsed and refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): results of a phase 1b/2 study. Blood (ASH Annual Meeting Abstracts). 2014;124:329.

    Article  Google Scholar 

  13. Blocksidge J, Glenn M, Gandhi AK, et al. CC-122 has robust anti-proliferative activity in a primary chronic lymphocytic leukemia (CLL) co-culture model and is superior to lenalidomide. Blood (ASH Annual Meeting Abstracts). 2014;124:4682.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine V, Laboratory for Clinical Oncogenomics, Innsbruck Medical University, Anichstr. 35, 6020, Innsbruck, Austria

    Michael Steurer MD

Authors
  1. Michael Steurer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael Steurer MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Steurer, M. Chronic lymphocytic leukemia: ASH update 2014. memo 8, 159–161 (2015). https://doi.org/10.1007/s12254-015-0223-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-015-0223-7

Keywords

Search

Navigation